Abstract
BackgroundLung cancer is the leading cause of cancer-related death worldwide. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. Despite careful case selection, a significant proportion of early-stage cancers relapse aggressively within the first year post-operatively. Identification of these patients is key to accurate prognostication and understanding the biology that drives early relapse might open up potential novel adjuvant therapies.MethodsWe performed an unsupervised interrogation of >1600 serum-based autoantibody biomarkers using an iterative machine-learning algorithm.ResultsWe identified a 13 biomarker signature that was highly predictive for survivorship in post-operative early-stage lung cancer; this outperforms currently used autoantibody biomarkers in solid cancers. Our results demonstrate significantly poor survivorship in high expressers of this biomarker signature with an overall 5-year survival rate of 7.6%.ConclusionsWe anticipate that the data will lead to the development of an off-the-shelf prognostic panel and further that the oncogenic relevance of the proteins recognised in the panel may be a starting point for a new adjuvant therapy.
Highlights
Worldwide, lung cancer is the leading cause of malignancyrelated death in men and the second in women
Identification of predictive biomarkers (Fig. 2) Initial data processing involved filtering according to the penetrance fold-change (pFC) analysis in order to avoid biasing subsequent model generation
Panel c was deemed a significant independent predictor of outcome only when entered into a DISCUSSION Results from the NLST and European NELSON trials were strongly supportive of lung cancer screening [18, 19]
Summary
Lung cancer is the leading cause of malignancyrelated death in men and the second in women. There are still a considerable proportion of patients with resectable lung cancers who relapse very quickly post resection. The behaviour of these cancers does not obey the expected outcomes based on prognostic scores such as the tumour node metastasis (TNM) staging system. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. A significant proportion of early-stage cancers relapse aggressively within the first year post-operatively. Identification of these patients is key to accurate prognostication and understanding the biology that drives early relapse might open up potential novel adjuvant therapies.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
